Skip to main content
Premium Trial:

Request an Annual Quote

Does it Wear a Cape?


Researchers at the University of Georgia and the Mayo Clinic have developed a cancer vaccine that they say could be effective against breast, prostate, pancreatic, bowel, and ovarian tumors, reports the UK Daily Mail's Fiona Macrae. In a mouse model, this so-called "super vaccine" shrank breast tumors by 80 percent, Macrae says. The researchers add that it could even work on drug-resistant tumors. Rather than attacking the tumors directly, the vaccine gets the immune system to do the fighting. The vaccine trains the immune system to go after cells with an overabundance of the MUC1 protein. As MUC1 is overexpressed in cancer cells, the idea is that such a vaccine would train the body to kill cancer cells while sparing healthy cells with normal MUC1 expression, Macrae says. In the end, the researchers say about 70 percent of cancers could be susceptible to this vaccine. While the tests so far have only been done on mice, the researchers plan to start testing on humans within the next two years.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.